These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 34779649)

  • 1. Structure-based molecular insights into matrix metalloproteinase inhibitors in cancer treatments.
    Lin H; Xu P; Huang M
    Future Med Chem; 2022 Jan; 14(1):35-51. PubMed ID: 34779649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential clinical applications of matrix metalloproteinase inhibitors and their future prospects.
    Li W; Saji S; Sato F; Noda M; Toi M
    Int J Biol Markers; 2013 Jun; 28(2):117-30. PubMed ID: 23787494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future Successes.
    Winer A; Adams S; Mignatti P
    Mol Cancer Ther; 2018 Jun; 17(6):1147-1155. PubMed ID: 29735645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural basis of matrix metalloproteinases and tissue inhibitors of metalloproteinases.
    Maskos K; Bode W
    Mol Biotechnol; 2003 Nov; 25(3):241-66. PubMed ID: 14668538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matrix metalloproteinase contribution in management of cancer proliferation, metastasis and drug targeting.
    Abdel-Hamid NM; Abass SA
    Mol Biol Rep; 2021 Sep; 48(9):6525-6538. PubMed ID: 34379286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors.
    Tauro M; Laghezza A; Loiodice F; Agamennone M; Campestre C; Tortorella P
    Bioorg Med Chem; 2013 Nov; 21(21):6456-65. PubMed ID: 24071448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seesaw of matrix metalloproteinases (MMPs).
    Kapoor C; Vaidya S; Wadhwan V; ; Kaur G; Pathak A
    J Cancer Res Ther; 2016; 12(1):28-35. PubMed ID: 27072206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding the binding of inhibitors of matrix metalloproteinases by molecular docking, quantum mechanical calculations, molecular dynamics simulations, and a MMGBSA/MMBappl study.
    Singh T; Adekoya OA; Jayaram B
    Mol Biosyst; 2015 Apr; 11(4):1041-51. PubMed ID: 25611160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Imaging Probes Based on Matrix Metalloproteinase Inhibitors (MMPIs).
    Rangasamy L; Geronimo BD; Ortín I; Coderch C; Zapico JM; Ramos A; de Pascual-Teresa B
    Molecules; 2019 Aug; 24(16):. PubMed ID: 31426440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress in the development of matrix metalloproteinase inhibitors.
    Tu G; Xu W; Huang H; Li S
    Curr Med Chem; 2008; 15(14):1388-95. PubMed ID: 18537616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matrix metalloproteinase inhibitors (MMPIs) as attractive therapeutic targets: Recent progress and current challenges.
    Shi Y; Ma X; Fang G; Tian X; Ge C
    NanoImpact; 2021 Jan; 21():100293. PubMed ID: 35559782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma.
    Naka T; Kuester D; Boltze C; Schulz TO; Samii A; Herold C; Ostertag H; Roessner A
    Hum Pathol; 2008 Feb; 39(2):217-23. PubMed ID: 17949787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Matrix Metalloproteinase-9 (MMP-9) Inhibitors in Cancer Treatment.
    Rashid ZA; Bardaweel SK
    Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The selectivity of galardin and an azasugar-based hydroxamate compound for human matrix metalloproteases and bacterial metalloproteases.
    Sylte I; Dawadi R; Malla N; von Hofsten S; Nguyen TM; Solli AI; Berg E; Adekoya OA; Svineng G; Winberg JO
    PLoS One; 2018; 13(8):e0200237. PubMed ID: 30075004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Matrix metalloproteinase-10/TIMP-2 structure and analyses define conserved core interactions and diverse exosite interactions in MMP/TIMP complexes.
    Batra J; Soares AS; Mehner C; Radisky ES
    PLoS One; 2013; 8(9):e75836. PubMed ID: 24073280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pigment epithelium-derived factor as a natural matrix metalloproteinase inhibitor: a comparison with classical matrix metalloproteinase inhibitors used for cancer treatment.
    Alcantara MB; Dass CR
    J Pharm Pharmacol; 2014 Jul; 66(7):895-902. PubMed ID: 24697787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is there new hope for therapeutic matrix metalloproteinase inhibition?
    Vandenbroucke RE; Libert C
    Nat Rev Drug Discov; 2014 Dec; 13(12):904-27. PubMed ID: 25376097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Matrix metalloproteinases and their role in pancreatic cancer: a review of preclinical studies and clinical trials.
    Bloomston M; Zervos EE; Rosemurgy AS
    Ann Surg Oncol; 2002 Aug; 9(7):668-74. PubMed ID: 12167581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matrix Metalloproteinases (MMPs) in Targeted Drug Delivery: Synthesis of a Potent and Highly Selective Inhibitor against Matrix Metalloproteinase- 7.
    Wang LL; Zhang B; Zheng MH; Xie YZ; Wang CJ; Jin JY
    Curr Top Med Chem; 2020; 20(27):2459-2471. PubMed ID: 32703131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural basis of the matrix metalloproteinases and their physiological inhibitors, the tissue inhibitors of metalloproteinases.
    Bode W; Maskos K
    Biol Chem; 2003 Jun; 384(6):863-72. PubMed ID: 12887053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.